PD 184352
| Code | Size | Price |
|---|
| AG-CR1-0029-M001 | 1 mg | £30.00 |
Quantity:
| AG-CR1-0029-M005 | 5 mg | £80.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; CI-1040
Appearance:
White to off-white solid.
CAS:
212631-79-3
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H302, H319
InChi:
InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)
InChiKey:
GFMMXOIFOQCCGU-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 212631-79-3. Formula: C17H14ClF2IN2O2. MW: 478.7. MEK (MAPKK) inhibitor. Potent and selective MAPK (ERK kinase 1; MEK1) activation inhibitor (IC50 = 300 nM in vitro, IC50 = 2 nM in vivo). Suppresses activation of MAPK but does not block its activity. Antiproliferative. Causes cell-cycle arrest in G1 phase. Tumor suppressor. Apoptosis inducer.
MDL:
MFCD02683961
Molecular Formula:
C17H14ClF2IN2O2
Molecular Weight:
478.7
Package Type:
Vial
Precautions:
P264, P270, P280, P301, P312
Product Description:
MEK (MAPKK) inhibitor [5]. Potent and selective MAPK (ERK kinase 1; MEK1) activation inhibitor (IC50 = 300 nM in vitro, IC50 = 2 nM in vivo) [1, 2]. Suppresses activation of MAPK but does not block its activity [3]. Antiproliferative [4]. Causes cell-cycle arrest in G1 phase [4]. Tumor suppressor [1, 5]. Apoptosis inducer [6].
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
FC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo: J.S. Sebolt-Leopold, et al.; Nat. Med. 5, 810 (1999) | Specificity and mechanism of action of some commonly used protein kinase inhibitors: S.P. Davies, et al.; Biochem. J. 351, 95 (2000) | Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352: A.M. Delaney, et al.; Mol. Cell. Biol. 22, 7593 (2002) | Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1: M.S. Squires, et al.; Biochem. J. 366, 673 (2002) | CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK): L.F. Allen, et al.; Semin. Oncol. 30, 105 (2003) (Review) | The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines: R.R. Mattingly, et al.; J. Pharmacol. Exp. Ther. 316, 456 (2006)